MetseraMTSR got a positive adjustment to its Relative Strength (RS) Rating, from 88 to 93.Please watch the video at Investors ...

Shares of Metsera Inc. (MTSR) have gained 6.8% over the past four weeks to close the last trading session at $35.32, but ...

Metsera is also joining its metabolic medicines peers who are developing oral GLP-1 drugs. The biotech’s candidate is MET-224o, an ultra-long acting GLP-1 receptor agonist made with technology ...

Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today anno Metsera Secures $215 Million Series B ...

Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin analog, which showed a mean weight loss of up to 8.4% at Day 36 after subtracting the placebo.

--Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, will highlight the breadth and momentum of its ...

Investment Overview - Metsera Latest To Join Obesity Market Challengers. Obesity is forecast by some analysts to become a >$200bn market, with up to 16 new drugs on the market by 2031. Eli Lilly ...

View Metsera, Inc. MTSR stock quote prices, financial information, real-time forecasts, and company news from CNN.

Metsera, Inc., a clinical-stage biopharmaceutical company focused on treating obesity and metabolic diseases, announced its first quarter 2025 financial results, highlighting significant progress ...

Metsera reports $156.26 million loss in first nine months of 2024 Proceeds from IPO to fund MET-097i clinical trials Weight-loss drug market projected to reach $150 billion by early 2030s Jan 10 ...

Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body weight compared to baseline at 36 days. While the biotech has yet to ...

Metsera is riding the wave of continued enthusiasm for GLP-1 drugs and its own early-stage data to bring in a hefty $215 million series B fundraise.. The biotech said it would use the cash to ...